How CDC Is making COVID-19 vaccine recommendations

Details

• Corporate Authors:
  National Center for Immunization and Respiratory Diseases (U.S.). Division of Viral Diseases.
• Description:
  Updated Dec. 18, 2020
  
  When the Food and Drug Administration (FDA) authorizes or approves a COVID-19 vaccine, ACIP will quickly hold a public meeting to review all available data about that vaccine (sign up to receive email updates whenever ACIP’s Meeting Information is updated). From these data, ACIP will then vote on whether to recommend the vaccine and, if so, who should receive it.
  
  • On December 1, 2020, ACIP made recommendations on who should be offered COVID-19 vaccination in the initial phase of the U.S. COVID-19 vaccination program while there is limited vaccine supply.
  
  • On December 11, 2020, the U.S. Food and Drug Administration issued an Emergency Use Authorization for use of the Pfizer-BioNTech COVID-19 vaccineexternal icon in persons aged 16 years and older for the prevention of COVID-19.
  
  • On December 13, 2020, the Advisory Committee on Immunization Practices (ACIP) issued recommendations for the use of Pfizer-BioNTech’s COVID-19 vaccine for the prevention of COVID-19.
  
  • On December 18, 2020, the U.S. FDA issued an Emergency Use Authorization for the use of the Moderna COVID-19 vaccineexternal icon for use in individuals 18 years of age and older.
  
  ACIP will meet again after FDA authorizes or approves other COVID-19 vaccines and will make recommendations for the use of individual vaccines at that time.
  
  
• Subjects:
  Coronavirus Infections/prevention & Control COVID-19 Vaccines Pandemics Patient Safety Vaccination Viral Vaccines
• Document Type:
  Webpage
• Place as Subject:
  United States
• Collection(s):
  Stephen B. Thacker CDC Library
• Main Document Checksum:
  urn:sha256:3dd342ec45ff7fb80a3b3558b339ab960d0185528b17f0643063664a9fa0c3d8
• Download URL:
  https://stacks.cdc.gov/view/cdc/99111/cdc_99111_DS1.pdf
• File Type:
  [PDF - 117.32 KB ]